

=> d his

(FILE 'HOME' ENTERED AT 13:45:13 ON 01 MAY 2003)

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 13:45:32 ON 01 MAY 2003

L1 8366 S (MOUSE OR MICE) (10W) (WEIGHT OR WEIGH)
L2 468 S. L1 AND (WEIGHT OR WEIGH) (15W)MG?
L3 344 DUP REM L2 (124 DUPLICATES REMOVED)

L15 ANSWER 10 OF 10 WPIDS (C) 2003 THOMSON DERWENT

AN 1994-279394 [34] WPIDS

CR 1999-243165 [20]

DNC C1994-127479

TI **Treatment** and prevention of insulin dependent **diabetes**
- by administering monoclonal antibodies specified for the integrin VLA4
blocking interactions with VCAM-1 and **fibronectin**.

DC B04 D16

IN BURKLY, L C; BURKLY, L

PA (BIOJ) BIOGEN INC

CYC 22

PI WO 9417828 A2 19940818 (199434)* 73p

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: AU CA JP NZ US

AU 9462379 A 19940829 (199501)

WO 9417828 A3 19941013 (199534)

EP 682529 A1 19951122 (199551) EN

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

NZ 262615 A 19960227 (199614)

JP 08508719 W 19960917 (199704) 66p

EP 682529 B1 19980107 (199806) EN 37p

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE 69407758 E 19980212 (199812)

AU 687790 B 19980305 (199820)

ES 2114183 T3 19980516 (199826)

AU 9869846 A 19980723 (199841)

AU 727187 B 20001207 (200103)

ADT WO 9417828 A2 WO 1994-US1456 19940209; AU 9462379 A AU 1994-62379
19940209, WO 1994-US1456 19940209; WO 9417828 A3 WO 1994-US1456 19940209;
EP 682529 A1 EP 1994-909584 19940209, WO 1994-US1456 19940209; NZ 262615 A
NZ 1994-262615 19940209; JP 08508719 W JP 1994-518333 19940209, WO
1994-US1456 19940209; EP 682529 B1 EP 1994-909584 19940209, WO 1994-US1456
19940209; DE 69407758 E DE 1994-607758 19940209, EP 1994-909584 19940209,
WO 1994-US1456 19940209; AU 687790 B AU 1994-62379 19940209; ES 2114183 T3
EP 1994-909584 19940209; AU 9869846 A Div ex AU 1994-62379 19940209, AU
1998-69846 19980602; AU 727187 B Div ex AU 1994-62379 19940209, AU
1998-69846 19980602

FDT AU 9462379 A Based on WO 9417828; EP 682529 A1 Based on WO 9417828; JP
08508719 W Based on WO 9417828; EP 682529 B1 Based on WO 9417828; DE
69407758 E Based on EP 682529, Based on WO 9417828; AU 687790 B Previous
Publ. AU 9462379, Based on WO 9417828; ES 2114183 T3 Based on EP 682529;
AU 727187 B Div ex AU 687790, Previous Publ. AU 9869846

PRAI US 1993-29330 19930209

AB WO 9417828 A UPAB: 20010116

A method for the prevention of insulin dependent (type 1) diabetes (IDD)
comprises administering to a prediabetic individual, a composition
comprising an anti-VLA4 (very late antigen) antibody (Ab).

Also claimed are (1) a method for the **treatment** of
diabetes comprising administering to a mammal with a
susceptibility to **diabetes**, an Ab, a recombinant Ab, a chimeric
Ab, fragments of such Abs, a polypeptide or small mol. capable of binding
to the alpha4 subunit of VLA4 or combinations of any of these, in an amt.
sufficient to inhibit the onset of diabetes; and (2) a pharmaceutical
compsn. consisting of a monoclonal Ab recognising VLA4 in a carrier.

Pref. the anti-VLA4 Ab is selected from HP1/2, HP2/1, HP2/4, L25 and
P4C2. It is esp. humanised HP1/2 or a fragment. Dosage is 0.1-10mg/kg; an
amt. effective to coat VLA4-positive cells in the peripheral blood for
1-14 days. This provides a plasma level of Ab of at least 1 ug/ml. The
compsn. is administered prior to the development of overt diabetes as
measured by a serum glucose level of less than about 250 mg/dl.

In the method of (1) the Ab/polypeptide is selected from AMb HP1/2

Fab, Fab', F(ab')₂ or F(v) fragments of such an antibody sol. VCAM-1, esp. VCAM 2D-IgG, or fibronectin polypeptides or small mols. that bind to the VCMA-1 or fibronectin binding domain of VLA4. The compsn. pref. comprises several anti-VLA4 MAbs or VLA4-binding fragments. It is administered at a dosage which provides 0.1-10 mg/kg body weight.

USE - The method provides a way of **treating diabetes** by administering a compsn. which binds to the VLA4 antigens on the surface of VLA4-positive cells, including lymphocytes and macrophages. This induces a change in the function of such cells by interferring with interactions between VLA4 antigens and either VCAM-1 or **fibronectin** on the surface of other cells. This in turn results in a prevention of or protection against the incidence of **diabetes**.
Dwg.0/8

=>

L15 ANSWER 8 OF 10 WPIDS (C) 2003 THOMSON DERWENT
 AN 1998-120309 [11] WPIDS
 DNC C1998-039493
 TI New cyclic peptide compounds - inhibit cell adhesion and may be used in
 treating asthma, psoriasis, **diabetes** or rheumatoid
 arthritis.
 DC B04
 IN DUTTA, A; DUTTA, A S
 PA (ZENE) ZENECA LTD
 CYC 79
 PI WO 9749731 A1 19971231 (199811)* EN 62p
 RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
 SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
 ZW
 ZA 9705436 A 19980225 (199813) 59p
 AU 9731027 A 19980114 (199822)
 NO 9805966 A 19981218 (199914)
 EP 910582 A1 19990428 (199921) EN
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 CN 1222918 A 19990714 (199946)
 NZ 332778 A 20000825 (200049)
 JP 2000513350 W 20001010 (200053) 72p
 MX 9810777 A1 19990401 (200055)
 KR 2000022075 A 20000425 (200105)
 US 6235711 B1 20010522 (200130)
 ADT WO 9749731 A1 WO 1997-GB1641 19970618; ZA 9705436 A ZA 1997-5436 19970619;
 AU 9731027 A AU 1997-31027 19970618; NO 9805966 A WO 1997-GB1641 19970618,
 NO 1998-5966 19981218; EP 910582 A1 EP 1997-926150 19970618, WO
 1997-GB1641 19970618; CN 1222918 A CN 1997-195724 19970618; NZ 332778 A NZ
 1997-332778 19970618, WO 1997-GB1641 19970618; J

d his

(FILE 'HOME' ENTERED AT 09:16:44 ON 01 MAY 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 09:17:03 ON 01 MAY 2003

SEA (SOLUBIL? OR STABIL?) (15W) PEPTIDE

18 FILE ADISCTI
5 FILE ADISINSIGHT
65 FILE AGRICOLA
23 FILE ANABSTR
14 FILE AQUASCI
75 FILE BIOBUSINESS
7 FILE BIOCOMMERCE
1632 FILE BIOSIS
138 FILE BIOTECHABS
138 FILE BIOTECHDS
721 FILE BIOTECHNO
82 FILE CABA
184 FILE CANCERLIT
2224 FILE CAPLUS
30 FILE CEABA-VTB

SEA (STABILITY) (15W) PEPTIDE

8 FILE ADISCTI
2 FILE ADISINSIGHT
25 FILE AGRICOLA
15 FILE ANABSTR
2 FILE AQUASCI
32 FILE BIOBUSINESS
679 FILE BIOSIS
59 FILE BIOTECHABS
59 FILE BIOTECHDS
296 FILE BIOTECHNO
36 FILE CABA
78 FILE CANCERLIT
1056 FILE CAPLUS
11 FILE CEABA-VTB
5 FILE CEN
6 FILE CONFSCI
2 FILE CROPB
1 FILE CROPU
19 FILE DDFB
49 FILE DDFU
1214 FILE DGENE
19 FILE DRUGB
3 FILE DRUGNL
79 FILE DRUGU
3 FILE DRUGUPDATES
4 FILE EMBAL
601 FILE EMBASE
359 FILE ESBIODASE
30 FILE FEDRIP
21 FILE FROSTI
31 FILE FSTA
4 FILE GENBANK
36 FILE IFIPAT
50 FILE JICST-EPLUS

1 FILE KOSMET
 230 FILE LIFESCI
 481 FILE MEDLINE
 1 FILE NIOSHTIC
 7 FILE NTIS
 184 FILE PASCAL
 1 FILE PHAR
 4 FILE PHIN
 27 FILE PROMT
 683 FILE SCISEARCH
 201 FILE TOXCENTER
 1634 FILE USPATFULL
 27 FILE USPAT2
 1 FILE VETB
 1 FILE VETU
 101 FILE WPIDS
 101 FILE WPINDEX

L1 QUE (STABILITY) (15W) PEPTIDE

 SEA L1 AND (STABILITY) (15W) IN VIVO

12 FILE BIOSIS
 1 FILE BIOTECHABS
 1 FILE BIOTECHDS
 8 FILE BIOTECHNO
 2 FILE CANCERLIT
 9 FILE CAPLUS
 3 FILE DDFU
 1 FILE DGENE
 4 FILE DRUGU
 13 FILE EMBASE
 7 FILE ESBIODASE
 1 FILE JICST-EPLUS
 7 FILE LIFESCI
 8 FILE MEDLINE
 5 FILE PASCAL
 1 FILE PROMT
 12 FILE SCISEARCH
 1 FILE TOXCENTER
 316 FILE USPATFULL
 6 FILE USPAT2
 2 FILE WPIDS
 2 FILE WPINDEX

L2 QUE L1 AND (STABILITY) (15W) IN VIVO

 FILE 'USPATFULL, EMBASE, BIOSIS, SCISEARCH, CAPLUS, BIOTECHNO, MEDLINE, ESBIODASE, LIFESCI, USPAT2, PASCAL, DRUGU, CANCERLIT, WPIDS, BIOTECHDS, DGENE, JICST-EPLUS, PROMT, TOXCENTER' ENTERED AT 09:21:02 ON 01 MAY 2003

L3 416 S L1 AND (STABILITY) (15W) IN VIVO

L4 349 DUP REM L3 (67 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 10:03:29 ON 01 MAY 2003

FILE 'USPATFULL' ENTERED AT 10:05:30 ON 01 MAY 2003

L5 77 S (HALF-LIFE OR STABILITY) (10W) IG

L6 21 S L5 AND PEPTIDE (25W) IG

L7 8 S L5 AND PEPTIDE (10W) IG

L8 31 S L5 AND PEPTIDE (10W) ANTIBOD?

L9 231 S L3 AND PEPTIDE (10W) ANTIBOD?

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,

BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 10:18:20 ON
01 MAY 2003

SEA IG(10W)STABILITY

1 FILE BIOBUSINESS
25 FILE BIOSIS
0* FILE BIOTECHABS
SEA STABILITY(10W)IN VIVO

16 FILE ADISCTI
8 FILE ADISINSIGHT
3 FILE ADISNEWS
35 FILE AGRICOLA
5 FILE ANABSTR
11 FILE AQUASCI
53 FILE BIOBUSINESS
2 FILE BIOCOMMERCE
811 FILE BIOSIS
0* FILE BIOTECHABS

=>

L4 ANSWER 310 OF 349 USPATFULL
AN 97:120596 USPATFULL
TI Bradykinin antagonist peptides incorporating N-substituted glycines
IN Goodfellow, Val S., Westminster, CO, United States
Marathe, Manoj V., Pittsburgh, PA, United States
Whalley, Eric T., Golden, CO, United States
Fitzpatrick, Timothy D., Boulder, CO, United States
Kuhlman, Karen G., Denver, CO, United States
PA Cortech, Inc., Denver, CO, United States (U.S. corporation)
PI US 5700779 19971223
AI US 1996-668100 19960620 (8)
RLI Continuation of Ser. No. US 1994-208115, filed on 9 Mar 1994, now
abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delaney,
Patrick R.
LREP Cushman Darby Cushman IP Group of Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides bradykinin type peptides containing
N-substituted glycines, particularly bradykinin antagonist peptides
useful for the treatment of conditions mediated by bradykinin including
pain and inflammation.